Health News

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today reported its financial results for the three and six months ended June 30, 2010.

Read more

Filed under: Pharmacy News
Tags: brain, gene, Pharmacy

Related posts

• University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD (0)
  University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain. Read more [tags] Pharmacy News [/tags]
  
  
• Neurologix third quarter net loss decreases to $2.3 million (0)
  Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system ("CNS"), today reported its financial results for the three and nine months ended September 30, 2010. Read more [tags] Pharmacy News [/tags]
  
  
• BDNF gene shows promise as target for treating obesity (0)
  With obesity reaching epidemic levels, researchers at the Ohio State University Medical Center are studying a potentially long-term treatment that involves injecting a gene directly into one of the critical feeding and weight control centers of the brain. Read more [tags] Pharmacy News [/tags]
  
  
• [11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment (0)
  Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer’s disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer [...]
  
  
• Zileuton can help reduce amyloid plaque formation and Alzheimer’s development (0)
  A drug used to treat asthma has been shown to help reduce the formation of amyloid beta, a peptide in the brain that is implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine. Read more [tags] Pharmacy News [/tags]